Edition:
United States

Resmed Inc (RMD.N)

RMD.N on New York Stock Exchange

77.33USD
12:14pm EDT
Change (% chg)

$0.01 (+0.01%)
Prev Close
$77.32
Open
$77.32
Day's High
$77.46
Day's Low
$77.14
Volume
28,899
Avg. Vol
368,881
52-wk High
$81.87
52-wk Low
$56.64

Chart for

About

ResMed Inc. is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD),... (more)

Overall

Beta: 0.78
Market Cap(Mil.): $10,995.61
Shares Outstanding(Mil.): 142.21
Dividend: 0.35
Yield (%): 1.81

Financials

  Industry Sector
P/E (TTM): -- 175.94 16.34
EPS (TTM): -- -- --
ROI: -- 9.47 14.66
ROE: -- 14.70 14.00

BRIEF-Resmed Q4 GAAP earnings per share $0.71

* Resmed Inc. announces results for the fourth quarter of fiscal year 2017

Aug 01 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 17 2017

BRIEF-Resmed plans to renew its patent infringement case against Fisher & Paykel

* Statement by ResMed on plans to renew its patent infringement case against Fisher & Paykel

May 17 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 16 2017

ResMed withdraws U.S. trade complaint against Fisher & Paykel Healthcare

WELLINGTON, May 17 Health appliance firm ResMed Inc has dropped a complaint against New Zealand's Fisher & Paykel Healthcare at the U.S. International Trade Commission (USITC), Fisher & Paykel said on Wednesday.

May 16 2017

BRIEF-Resmed Q3 gaap earnings per share $0.62

* Resmed Inc. Announces results for the third quarter of fiscal year 2017

Apr 27 2017

BRIEF-ResMed provides data on patients with untreated sleep apnea

* New resmed-sponsored study shows promising treatment option for patients with untreated central sleep apnea Source text for Eikon: Further company coverage:

Apr 06 2017

Earnings vs. Estimates